RESCRIPTOR Tablets contain delavirdine mesylate, a synthetic non-nucleoside reverse transcriptase inhibitor of the human immunodeficiency virus type 1 (HIV-1). The chemical name of delavirdine mesylate is piperazine, 1-[3-[(1-methyl-ethyl)amino]-2- pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H- indol-2-yl]carbonyl]-, monomethanesulfonate. Its molecular formula is C22H28N6O3S * CH4O3S, and its molecular weight is 552.68. The structural formula is: Delavirdine mesylate is an odorless white-to-tan crystalline powder. The aqueous solubility of delavirdine free base at 23 degC is 2942 mg/mL at pH 1.0, 295 mg/mL at pH 2.0, and 0.81 mg/mL at pH 7.4. Each RESCRIPTOR Tablet, for oral administration, contains 100 or 200 mg of delavirdine mesylate (henceforth referred to as delavirdine). Inactive ingredients consist of lactose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, and carnauba wax. In addition, the 100-mg tablet contains Opadry White YS-1-7000-E and the 200-mg tablet contains hydroxypropyl methylcellulose, Opadry White YS-1-18202-A and Pharmaceutical Ink Black.
Delavirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-
1. Delavirdine binds directly to reverse transcriptase (RT) and blocks RNA-dependent and DNA- dependent DNA polymerase activities. Delavirdine does not compete with template: primer or deoxynucleoside triphosphates. HIV-2 RT and human cellular DNA polymerases a, g, or d are not inhibited by delavirdine. In addition, HIV-1 group O, a group of highly divergent strains that are uncommon in North America, may not be inhibited by delavirdine. In vitro HIV-1 susceptibility: In vitro anti-HIV-1 activity of delavirdine was assessed by infecting cell lines of lymphoblastic and monocytic origin and peripheral blood lymphocytes with laboratory and clinical isolates of HIV-1. IC50 and IC90 values (50% and 90% inhibitory concentrations) for laboratory isolates (N=5) ranged from 0.005 to 0.030 mM and 0.04 to 0.10 mM, respectively. Mean IC50 of clinical isolates (N=74) was 0.038 mM (range 0.001 to 0.69 mM); 73 of 74 clinical isolates had an IC50 PS 0.18 mM. The IC90 of 24 of these clinical isolates ranged from 0.05 to 0.10 mM. In drug combination studies of delavirdine with zidovudine, didanosine, zalcitabine, lamivudine, interferon-a, and protease inhibitors, additive to synergistic anti-HIV-1 activity was observed in cell culture. The relationship between the in vitro susceptibility of HIV-1 RT inhibitors and the inhibition of HIV replication in humans has not been established.
Drug Resistance
: Phenotypic analyses of isolates from patients treated with RESCRIPTOR as monotherapy showed a 50-fold to 500-fold reduced susceptibility in 14 of 15 patients by week 8 of therapy. Genotypic analysis of HIV-1 isolates from patients receiving RESCRIPTOR plus zidovudine combination therapy (N=79) showed resistance conferring mutations in all isolates by week 24 of therapy. In RESCRIPTOR treated patients the mutations in RT occurred predominantly at amino acid positions 103 and less frequently at positions 181 and 236. In a separate study, an average of 86-fold increase in the zidovudine susceptibility of patient isolates (N=24) was observed after 24-weeks of RESCRIPTOR and zidovudine combination therapy. The clinical relevance of the phenotypic and the genotypic changes associated with RESCRIPTOR therapy has not been established.
Cross-resistance
: RESCRIPTOR may confer cross-resistance to other non-nucleoside RT inhibitors when used alone or in combination. Mutations at positions 103 and/or 181 has been found in resistant virus during treatment with RESCRIPTOR and other non-nucleoside RT inhibitors. These mutations have been associated with cross-resistance among non-nucleoside RT inhibitors in vitro.
Absorption and Bioavailability: Delavirdine is rapidly absorbed following oral administration, with peak plasma concentrations occurring at approximately one hour. Following administration of delavirdine 400 mg tid (n=67, HIV-1-infected patients), the mean +- SD steady-state peak plasma concentration (Cmax) was 35 +- 20 mM (range 2 to 100 mM), systemic exposure (AUC) was 180 +- 100 mM * hr (range 5 to 515 mM * hr) and trough concentration (Cmin) was 15 +- 10 mM (range 0.1 to 45 mM). The single-dose bioavailability of delavirdine tablets relative to an oral solution was 85 +- 25% (n=16, non-HIV-infected subjects). The single-dose bioavailability of delavirdine tablets (100 mg strength) was increased by approximately 20% when a slurry of drug was prepared by allowing delavirdine tablets to disintegrate in water before administration (n=16, non-HIV-infected subjects). The bioavailability of the 200 mg strength delavirdine tablets has not been evaluated when administered as a slurry, because they are not readily dispersed in water (see DOSAGE AND ADMINISTRATION). Delavirdine may be administered with or without food. In a multiple-dose, cross-over study, delavirdine was administered every eight hours with food or every eight hours, one hour before or two hours after a meal (n=13, HIV-1-infected patients). Patients remained on their typical diet throughout the study; meal content was not standardized. When multiple doses of delavirdine were administered with food, geometric mean Cmax was reduced by approximately 25% but AUC and Cmin were not altered. Distribution: Delavirdine is extensively bound (approximately 98%) to plasma proteins, primarily albumin. The percentage of delavirdine that is protein bound is constant over a delavirdine concentration range of 0.5 to 196 mM. In five HIV-1-infected patients whose total daily dose of delavirdine ranged from 600 to 1200 mg, cerebrospinal fluid concentrations of delavirdine averaged 0.4% +- 0.07% of the corresponding plasma delavirdine concentrations; this represents about 20% of the fraction not bound to plasma proteins. Steady-state delavirdine concentrations in saliva (n=5, HIV-1- infected patients who received delavirdine 400 mg tid) and semen (n=5 healthy volunteers who received delavirdine 300 mg tid) were about 6% and 2%, respectively, of the corresponding plasma delavirdine concentrations collected at the end of a dosing interval. Metabolism and Elimination: Delavirdine is extensively converted to several inactive metabolites. Delavirdine is primarily metabolized by cytochrome P450 3A (CYP3A), but in vitro data suggest that delavirdine may also be metabolized by CYP2D6. The major metabolic pathways for delavirdine are N- desalkylation and pyridine hydroxylation. Delavirdine exhibits nonlinear steady-state elimination pharmacokinetics, with apparent oral clearance decreasing by about 22-fold as the total daily dose of delavirdine increases from 60 to 1200 mg/day. In a study of 14C-delavirdine in six healthy volunteers who received multiple doses of delavirdine tablets 300 mg tid, approximately 44% of the radiolabeled dose was recovered in feces, and approximately 51% of the dose was excreted in urine. Less than 5% of the dose was recovered unchanged in urine. The parent plasma half-life of delavirdine increases with dose; mean half-life following 400 mg tid is 5.8 hours, with a range of 2 to 11 hours.
In vitro and in vivo studies have shown that delavirdine reduces CYP3A activity and inhibits its own metabolism. In vitro studies have also shown that delavirdine reduces CYP2C9, CYP2D6, and CYP2C19 activity. Inhibition of hepatic CYP3A activity by delavirdine is reversible within 1 week after discontinuation of drug.
Hepatic or Renal Impairment:
The pharmacokinetics of delavirdine in patients with hepatic or renal impairment have not been investigated (see PRECAUTIONS).
Age:
The pharmacokinetics of delavirdine have not been adequately studied in patients <16 years or
>65 years of age.
Gender:
Data from population pharmacokinetics suggest that the plasma concentrations of delavirdine tend to be higher in females than in males. However, this difference is not considered to be clinically significant.
Race:
No significant differences in the mean trough delavirdine concentrations were observed between different racial or ethnic groups.
Specific drug interaction studies were performed with delavirdine and a number of drugs. Table 1 summarizes the effects of delavirdine on the geometric mean AUC, Cmax and Cmin of coadministered drugs. Table 2 shows the effects of coadministered drugs on the geometric mean AUC, Cmax and Cmin of delavirdine. For information regarding clinical recommendations, see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS: Drug Interactions.
| Coadministere d Drug | Dose of Coadministere d Drug | Dose of RESCRIPTO R | n | % Change in Pharmacokinetic Parameters of Coadministered Drug (90% CI) | ||
| Cmax | AUC | Cmin | ||||
| HIV-Protease Inhibitors | ||||||
| Indinavir | 400 mg tid x | 400 mg tid x 7 | 2 | | 36 * | - | |118 * |
| days | days | 8 | ( | 52- | 14) | (|16-|312) | ||
| 600 mg tid x | 400 mg tid x 7 | 2 | - | |53 * | |298 * | |
| 7 days | days | 8 | (|7-|120) | (|104- | ||
| |678) | ||||||
| Nelfinavir * * | 750 mg tid x | 400 mg tid x 7 | 1 | |88 | |107 | |136 |
| 14 days | days | 2 | (|66-|113) | (|83-|135) | (|103- | |
| |175) | ||||||
| Saquinavir | Soft gel | 400 mg tid x | 2 | |98++ | |121++ | |199++ |
| capsule 1000 | 28 days | 0 | (|4-|277) | (|14-|340) | (|37-|553) | |
| mg tid x 28 | ||||||
| days | ||||||
| Nucleoside Reverse Transcriptase Inhibitors | ||||||
| Didanosine | 125 or 250 mg | 400 mg tid x | 9 | |20SS | |21SS | - |
| (buffered | bid x 28 days | 28 days | (|44-|15) | (|40-|5) | ||
| tablets) | ||||||
| Zidovudine | 200 mg tid for >38 days | 100 mg qid to 400 mg tid for 8-10 days | 3 4 | - | - | - |
| Anti-infective Agents | ||||||
| Clarithromyci n | 500 mg bid x 15 days | 300 mg tid x 30 days | 6 | - | |100 | - |
| Rifabutin | 300 mg qd for | 400-1000 mg | 5 | |128 | |230 | |452 |
| 15-99days | tid for 45-129 | (|71-|203) | (|119- | (|246- | ||
| days | |396) | |781) | ||||
| Indicates increase | Indicates decrease
- Indicates no significant change
* Relative to indinavir 800 mg tid without RESCRIPTOR
* * Plasma concentrations of the nelfinavir active metabolite (nelfinavir hydroxy-t-butylamide) were significantly reduced by delavirdine, which is more than compensated for by increased nelfinavir concentration.
++ Saquinavir soft gel capsule 1000 mg tid plus RESCRIPTOR 400 mg tid relative to saquinavir soft gel capsule
1200 mg tid without RESCRIPTOR
SS RESCRIPTOR taken with didanosine (buffered tablets) relative to doses of RESCRIPTOR and didanosine (buffered tablets) separated by at least 1 hr - No data available
Table 2. Pharmacokinetic Parameters for Delavirdine in the Presence of Coadministered Drugs | ||||||
|---|---|---|---|---|---|---|
| Coadministered Drug | Dose of Coadminister ed Drug | Dose of RESCRIPTO R | n | % Change in Delavirdine Pharmacokinetic Parameters (90% CI) | ||
| Cmax | AUC | Cmin | ||||
| HIV-Protease Inhibitors | ||||||
| Indinavir | 400 or 600 mg tid x 7 days | 400 mg tid x 7 days | 81 | No apparent changes based on a comparison to historical data | ||
| Nelfinavir | 750 mg tid x 7 days | 400 mg tid x 14 days | 7 | |27 (|49-|4) | |31 (|57-|10) | |33 (|70-|49) |
| Saquinavir | Soft gel capsule 1000 mg tid x 28 days | 400 mg tid for 7-28 days | 23 | No apparent changes based on a comparison to historical data | ||
| Nucleoside Reverse Transcriptase Inhibitors | ||||||
| Didanosine (buffered tablets) | 125 or 200 mg bid x 28 days | 400 mg tid x 28 days | 9 | |32+ (|48-|11) | |19+ (|37-|6) | -+ |
| Zidovudine | 200 mg tid for >= 7 days | 400 mg tid for 7-14 days | 42 | No apparent changes based on a comparison to historical data | ||
| Anti-infective Agents | ||||||
| Clarithromycin | 500 mg bid x 15 days | 300 mg tid x 30 days | 6 | - | - | - |
| Fluconazole | 400 mg qd x 15 days | 300 mg tid x 30 days | 8 | - | - | - |
| Ketoconazole | Various | 200-400 mg tid | 26 | - | - | |50++ |
| Rifabutin | 300 mg qd x 14 days | 400 mg tid x 28 days | 7 | | 72 (|61-|80) | |82 (|74-|88) | |94 (|90-|96) |
| Rifampin | 600 mg qd x 15 days | 400 mg tid x 30 days | 7 | |90 (|94-|83) | |97 (|98-|95) | |100 |
| Sulfamethoxazo le or Trimethoprim & Sulfamethoxazo le | Various | 200-400 mg tid | 311 | - | - | -++ |
| Other | ||||||
| Antacid (Maalox(r) TC) | 20 mL | 300 mg Single-Dose | 12 | |52 (|68-|29) | |44 (|58-|27) | - |
| Fluoxetine | Various | 200-400 mg tid | 36 | - | - | |50++ |
| Phenytoin, Phenobarbital, Carbamazepine | Various | 300-400 mg tid | 8 | - | - | |90++ |
| Indicates increase | Indicates decrease - Indicates no significant change + RESCRIPTOR taken with didanosine (buffered tablets) relative to doses of RESCRIPTOR and didanosine (buffered tablets) separated by at least 1 hr ++Population pharmacokinetic data from efficacy studies - No data available
RESCRIPTOR Tablets are indicated for the treatment of HIV-1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted. The following should be considered before initiating therapy with Rescriptor in treatment naive patients. There are insufficient data directly comparing Rescriptor containing antiretroviral regimens with currently preferred 3-drug regimens for initial treatment of HIV. In studies comparing regimens consisting of 2 NRTI's (currently considered suboptimal) to Rescriptor plus 2 NRTIs, the proportion of patients receiving the Rescriptor regimen who achieved and sustained an HIV-1 RNA level < 400 copies/mL over 1 year of therapy was relatively low (See DESCRIPTION OF CLINICAL STUDIES). Resistant virus emerges rapidly when RESCRIPTOR is administered as monotherapy. Therefore, RESCRIPTOR should always be administered in combination with other antiretroviral agents.
For clinical studies 21 Part II and 13C described below, efficacy was evaluated by the percentage of patients with a plasma HIV RNA level < 400 copies/mL through week 52 as measured by the Roche AmplicorO HIV-1 Monitor (standard assay). An intent-to-treat analysis was performed where only subjects who achieved confirmed suppression and sustained it through Week 52 are regarded as responders. All other subjects (including never suppressed, discontinued, and those who rebounded after initial suppression of < 400 copies/mL) are considered failures at Week 52. Results of an interim analysis of efficacy conducted for studies 21 Part II and 13C by independent Data and Safety Monitoring Boards (DSMBs) revealed that the triple therapy arms in both studies produced significantly greater antiviral benefit than the dual therapy arms and early termination of the studies was recommended. Study 21 Part II: Study 21 Part II was a double-blind, randomized, placebo controlled trial comparing treatment with RESCRIPTOR (400mg tid), zidovudine (ZDV; 200mg tid) and lamivudine (3TC; 150mg bid) versus RESCRIPTOR (400mg tid) and zidovudine (200mg tid) versus zidovudine (200mg tid) and lamivudine (150mg bid) in 373 HIV-1 infected patients (mean age 35 years [range 17 to 67], 87% male and 60% Caucasian) who were antiretroviral treatment naive (84%) or had limited nucleoside experience (16%). Mean baseline CD4 cell count was 359 cells/mm3 and mean baseline plasma HIV RNA was 4.4 log10 copies/mL. Results showed that the mean increase from baseline in CD4 count at 52 weeks was 111 cells/mL for RESCRIPTOR + ZDV + 3TC, 27 cells/mL for RESCRIPTOR + ZDV, and 74 cells/mL for ZDV + 3TC. The results of the intent-to-treat analysis of the percentage of patients with a plasma HIV RNA level
<
400 copies/mL are presented in Figure 1. HIV-1 RNA status and reasons for discontinuation of randomized treatment at 52 weeks are summarized in Table 3. Subjects who were never suppressed before discontinuation were placed in the discontinuation category.
Figure 1
Percentage of Patients with HIV RNA Below 400 copies/mL
Standard PCR Assay Protocol 21 Part 2 Intent-to-Treat Analysis
Percentage of Patients with HIV-1 RNA
<400 copies/mL
| DLV+ZDV+3TC ZDV+3TC DLV+ZDV | |
0 4 8 12 16 20 24 28 32 36 40 44 48 52
Study Week
| Outcome | ZDV + 3TC N = 124 % | DLV + ZDV N= 125 % | DLV + ZDV + 3TC N = 124 % |
| HIV RNA < 400 copies/mL * | 14 | 2 | 45 |
| HIV RNA > 400 copies/mL + ,++ | 64 | 52 | 31 |
| Discontinued due to adverse events ++ | 8 | 13 | 10 |
| Discontinued due to other reasons ++ , SS | 14 | 33 | 14 |
+
Virologic failures at or before Week 52.
++
Considered to be treatment failure in the analysis.
SS
Includes discontinuations due to consent withdrawn, loss to follow-up, protocol violations, non- compliance, pregnancy, never treated, and other reasons.
Study 13C: Study 13C was a double-blind, randomized, placebo controlled trial comparing treatment with RESCRIPTOR (400mg tid), zidovudine (200mg tid or 300 bid) and either didanosine (ddI; 200mg bid), zalcitabine (ddC; 0.75mg tid) or lamivudine (150mg bid) versus zidovudine (200mg tid or 300 bid) and either didanosine (200mg bid), zalcitabine (0.75mg tid) or lamivudine (150mg bid) in 345 HIV-1 infected patients (mean age 35.8 years [range 18 to 72], 66% male and 63% Caucasian) who were antiretroviral treatment naive (63%) or had limited antiretroviral experience (37%). Mean baseline CD4 cell count was 210 cells/mm3 and mean baseline plasma HIV RNA was 4.9 log10 copies/mL. Results showed that the mean increase from baseline in CD4 count at 54 weeks was 102 cells/mL for RESCRIPTOR + ZDV + ddI or ddC or 3TC and 56 cells/mL for ZDV + ddI or ddC or 3TC. The results of the intent-to-treat analysis of the percentage of patients with a plasma HIV RNA level
<
400 copies/mL are presented in Figure 2. HIV-1 RNA status and reasons for discontinuation of randomized treatment at 54 weeks are summarized in Table 4. Subjects who were never suppressed before discontinuation were placed in the discontinuation category.
Figure 2
Percentage of Patients with HIV RNA Below 400 copies/mL
Standard PCR Assay Protocol 13C
Intent-to-Treat Analysis
Percentage of Patients With HIV-1 RNA
<400 copies/mL
| ZDV+ddx+DLV ZDV+ddx | |
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56
Study Week
| Outcome | ZDV + ddx * * N = 173 % | ZDV + ddx + DLV N= 172 % |
| HIV RNA < 400 copies/mL * | 10 | 29 |
| HIV RNA >= 400 copies/mL + ,++ | 69 | 42 |
| Discontinued due to adverse events ++ | 7 | 12 |
| Discontinued due to other reasons ++ , SS | 14 | 17 |
+
Virologic failures at or before Week 54.
++
Considered to be treatment failure in the analysis.
SS
Includes discontinuations due to constant withdrawn, loss to follow-up, protocol violations, non- compliance, pregnancy, never treated, and other reasons.
Results from several smaller supportive studies evaluating the use of Rescriptor in treatment naive patients suggest that it may have activity when used in combination with protease inhibitors and NRTIs in 3 or 4 drug combinations.
RESCRIPTOR Tablets are contraindicated in patients with known hypersensitivity to any of its ingredients. Coadministration of RESCRIPTOR is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. These drugs are listed in Table 5. Also, see PRECAUTIONS, Table 6: Drugs that should not be coadministered with RESCRIPTOR.
Table 5: Drugs That Are Contraindicated With RESCRIPTOR
| Drug Class | Drugs Within Class That Are Contraindicated With RESCRIPTOR |
| Antihistamines | Astemizole, Terfenadine |
| Ergot Derivatives | Dihydroergotamine, Ergonovine, Ergotamine, Methylergonovine |
| GI motility agent | Cisapride |
| Neuroleptic | Pimozide |
| Sedative/hypnotics | Alprazolam, Midazolam, Triazolam |
This statement is included on the product's bottle label.
Because delavirdine may inhibit the metabolism of many different drugs (e.g., antiarrhythmics, calcium channel blockers, sedative hypnotics and others), serious and/or life threatening drug interactions could result from inappropriate coadministration of some drugs with delavirdine. In addition, some drugs may markedly reduce delavirdine plasma concentrations, resulting in suboptimal antiviral activity and subsequent emergence of drug resistance. All prescribers should become familiar with the following tables in this package insert: Table 5, Drugs That Are Contraindicated with Rescriptor; Table 6, Drugs That Should Not Be Co-administered With RESCRIPTOR; and Table 7, Established and Other Potentially Significant Drug Interactions for Which Alteration in Dose or Regimen May Be Recommended. Additional details on drug interactions can be found in Tables 1 and 2 under the Clinical Pharmacology Section. Concomitant use of lovastatin or simvastatin with RESCRIPTOR is not recommended. Caution should be exercised if RESCRIPTOR is used concurrently with other HMG-CoA reductase inhibitors that are also metabolized by the CYP3A4 pathway (e.g., atorvastatin or cerivastatin). The risk of myopathy including rhabdomyolysis may be increased when RESCRIPTOR is used in combination with these drugs. Particular caution should be used when prescribing sildenafil in patients receiving RESCRIPTOR. Coadministration of sildenafil with RESCRIPTOR is expected to substantially increase sildenafil concentrations and may result in an increase in sildenafil-associated adverse events, including hypotension, visual changes, and priapism (see PRECAUTIONS, Drug Interactions and Information for Patients, and the complete prescribing information for sildenafil). Concomitant use of St. John's wort (hypericum perforatum) or St. John's wort containing products and RESCRIPTOR is not recommended. Coadministration of St. John's wort with non-nucleoside reverse transcriptase inhibitors (NNRTIs), including RESCRIPTOR, is expected to substantially decrease NNRTI concentrations and may result in sub-optimal levels of RESCRIPTOR and lead to loss of virologic response and possible resistance to RESCRIPTOR or to the class of NNRTIs.
Delavirdine is metabolized primarily by the liver. Therefore, caution should be exercised when administering RESCRIPTOR Tablets to patients with impaired hepatic function.
Non-nucleoside reverse transcriptase inhibitors, when used alone or in combination, may confer cross-resistance to other non-nucleoside reverse transcriptase inhibitors.
Erythema multiforme and Stevens- Johnson syndrome were rarely seen in clinical trials and resolved after withdrawal of RESCRIPTOR.
Any patient experiencing severe rash or rash accompanied by symptoms such as fever, blistering, oral lesions, conjunctivitis, swelling, muscle or joint aches should discontinue RESCRIPTOR and consult a physician. Two cases of Stevens-Johnson syndrome have been reported through post-marketing surveillance out of a total of 339 surveillance reports. In studies 21 Part II and 13C (see DESCRIPTION OF CLINICAL STUDIES), rash (including maculopapular rash) was reported in more patients who were treated with RESCRIPTOR 400 mg tid (35% and 32%, respectively) than in those who were not treated with RESCRIPTOR (21% and 16%, respectively). The highest intensity of rash reported in these studies was severe (grade 3), which was observed in approximately 4% of patients treated with RESCRIPTOR in each study and in none of the patients who were not treated with RESCRIPTOR. Also in studies 21 Part II and 13C, discontinuations due to rash were reported in more patients who received RESCRIPTOR 400 mg tid (3% and 4%, respectively) than in those who did not receive RESCRIPTOR (0 and 1%, respectively) In most cases, the duration of the rash was less than 2 weeks and did not require dose reduction or discontinuation of RESCRIPTOR. Most patients were able to resume therapy after rechallenge with RESCRIPTOR following a treatment interruption due to rash. The distribution of the rash was mainly on the upper body and proximal arms, with decreasing intensity of the lesions on the neck and face, and progressively less on the rest of the trunk and limbs. Occurrence of a delavirdine-associated rash after 1 month is uncommon. unless prolonged interruption of treatment with RESCRIPTOR occurs. Symptomatic relief has been obtained using diphenhydramine hydrochloride, hydroxyzine hydrochloride, and/or topical corticosteroids.
A statement to patients and health care providers is included on the product's bottle label:
A patient package insert (PPI) for RESCRIPTOR is available for patient information.
Patients should be informed that RESCRIPTOR is not a cure for HIV-1 infection and that they may continue to acquire illnesses associated with HIV-1 infection, including opportunistic infections. Treatment with RESCRIPTOR has not been shown to reduce the incidence or frequency of such illnesses, and patients should be advised to remain under the care of a physician when using RESCRIPTOR. Patients should be advised that the use of RESCRIPTOR has not been shown to reduce the risk of transmission of HIV-1. Patients should be instructed that the major toxicity of RESCRIPTOR is rash and should be advised to promptly notify their physician should rash occur. The majority of rashes associated with RESCRIPTOR occur within 1 to 3 weeks after initiating treatment with RESCRIPTOR. The rash normally resolves in 3 to 14 days and may be treated symptomatically while therapy with RESCRIPTOR is continued. Any patient experiencing severe rash or rash accompanied by symptoms such as fever, blistering, oral lesions, conjunctivitis, swelling, muscle or joint aches should discontinue medication and consult a physician. Patients should be informed to take RESCRIPTOR every day as prescribed. Patients should not alter the dose of RESCRIPTOR without consulting their doctor. If a dose is missed, patients should take the next dose as soon as possible. However, if a dose is skipped, the patient should not double the next dose. Patients with achlorhydria should take RESCRIPTOR with an acidic beverage (eg, orange or cranberry juice). However, the effect of an acidic beverage on the absorption of delavirdine in patients with achlorhydria has not been investigated. Patients taking both RESCRIPTOR and antacids should be advised to take them at least one hour apart. Because RESCRIPTOR may interact with certain drugs, patients should be advised to report to their doctor the use of any prescription, non-prescription medication or herbal products, particularly St. John's wort. Patients receiving sildenafil and RESCRIPTOR should be advised that they may be at an increased risk of sildenafil-associated adverse events, including hypotension, visual changes, and prolonged penile erection, and should promptly report any symptoms to their doctor.
Delavirdine is an inhibitor of CYP3A isoform and other CYP isoforms to a lesser extent including CYP2C9, CYP2D6, and CYP2C19. Coadministration of RESCRIPTOR and drugs primarily metabolized by CYP3A (e.g., HMG-CoA reductase inhibitors and sildenafil) may result in increased plasma concentrations of the coadministered drug that could increase or prolong both its therapeutic or adverse effects. Delavirdine is metabolized primarily by CYP3A, but in vitro data suggest that delavirdine may also be metabolized by CYP2D6. Coadministration of RESCRIPTOR and drugs that induce CYP3A, such as rifampin, may decrease delavirdine plasma concentrations and reduce its therapeutic effect. Coadministration of RESCRIPTOR and drugs that inhibit CYP3A may increase delavirdine plasma concentrations. See Table 6: Drugs that should not be coadministered with RESCRIPTOR and Table 7: Drug interactions in which alteration and dose regimen may be recommended.
| Drug Class: Drug Name | Clinical Comment |
| Anticonvulsant Agents: Phenytoin, phenobarbital, carbamazepine | May lead to loss of virologic response and possible resistance to RESCRIPTOR or to the class of non-nucleoside reverse transcriptase inhibitors. |
| Antihistamines: astemizole, terfenadine | CONTRAINDICATED due to potential for serious and/or life- threatening reactions such as cardiac arrhythmias. |
| Antimycobacterials: rifabutin *, rifampin * | May lead to loss of virologic response and possible resistance to RESCRIPTOR or to the class of non-nucleoside reverse transcriptase inhibitors or other co-administered antiviral agents. |
| Ergot Derivatives: dihydroergotamine, | CONTRAINDICATED due to potential for serious and/or life threatening reactions such as acute ergot toxicity characterized by |
| ergonovine, ergotamine, methylergonovine | peripheral vasospasm and ischemia of the extremities and other tissues. |
| GI Motility Agent: cisapride | CONTRAINDICATED due to potential for serious and/or life- threatening reactions such as cardiac arrhythmias. |
| Herbal Products: St. John's wort (hypericum perforatum) | May lead to loss of virologic response and possible resistance to RESCRIPTOR or to the class of non-nucleoside reverse transcriptase inhibitors. |
| HMG-CoA Reductase Inhibitors: lovastatin, simvastatin | Potential for serious reactions such as risk of myopathy including rhabdomyolysis. |
| Neuroleptic: pimozide | CONTRAINDICATED due to potential for serious and/or life- threatening reactions such as cardiac arrhythmias. |
| Sedative/Hypnotics: alprazolam, midazolam, triazolam | CONTRAINDICATED due to potential for serious and/or life- threatening reactions such as prolonged or increased sedation or respiratory depression. |
* See CLINICAL PHARMACOLOGY for magnitude of interaction, Tables 1 and 2.
| Concomitant Drug Class: Drug Name | Effect on Concentration of delavirdine or Concomitant Drug | Clinical Comment |
| HIV-Antiviral Agents | ||
| Amprenavir | | Amprenavir | Appropriate doses of this combination with respect to safety, efficacy and pharmacokinetics have not been established. |
| Didanosine * | | Delavirdine | Didanosine | Administration of didanosine (buffered tablets) and RESCRIPTOR should be separated by at least one hour. |
| Indinavir * | | Indinavir | A dose reduction of indinavir to 600mg tid should be considered when RESCRIPTOR and indinavir are coadministered. |
| Lopinavir/Ritonavir | | Lopinavir | Ritonavir | Appropriate doses of this combination with respect to safety, efficacy and pharmacokinetics have not been established. |
| Nelfinavir * | | Nelfinavir | Delavirdine | Appropriate doses of this combination with respect to safety, efficacy and pharmacokinetics have not been established. See CLINICAL PHARMACOLOGY : Tables 1 and 2. |
| Ritonavir | | Ritonavir | Appropriate doses of this combination with respect to safety, efficacy and pharmacokinetics have not been established. |
| Saquinavir * | | Saquinavir | A dose reduction of saquinavir (soft gelatin capsules) may be considered when RESCRIPTOR and saquinavir are coadministered. See CLINICAL PHARMACOLOGY : Table 1. Appropriate doses with respect to safety, efficacy and pharmacokinetics have not been established. |
| Other Agents | ||
| Acid Blockers: Antacids * H 2 Receptor Antagonists: Cimetidine, Famotidine, Nizatidine, Ranitidine, Proton Pump Inhibitors, Omeprazole, Lansoprazole | | Delavirdine | Doses of an antacid and RESCRIPTOR should be separated by at least one hour, because the absorption of delavirdine is reduced when coadministered with antacids. |
| These agents increase gastric pH and may reduce the absorption of delavirdine. Although the effect of these drugs on delavirdine absorption has not been evaluated, chronic use of these drugs with RESCRIPTOR is not recommended. | ||
| Amphetamine | | Amphetamines | Use with caution. |
| Antiarrhythmics: Bepridil Amiodarone, lidocaine(systemic), quinidine, flecainide, propafenone | | Antiarrhythmics | Use with caution. Increased bepridil exposure may be associated with life-threatening reactions such as cardiac arrhythmias. |
| Caution is warranted and therapeutic concentration monitoring is recommended, if available, for antiarrhythmics when coadministered with RESCRIPTOR. | ||
| Anticoagulant: Warfarin | | Warfarin | It is recommended that INR (international normalized ratio) be monitored. |
| Anti-infective: Clarithromycin * | | Clarithromycin | When coadministered with RESCRIPTOR, clarithromycin should be adjusted in patients with impaired renal function: For patients with CL C R 30 to 60 mL/min the dose of clarithromycin should be reduced by 50%. For patients with CL C R <30 mL/min the dose of clarithromycin should be reduced by 75%. |
| Calcium Channel Blockers, Dihydropyridine: e.g., amlodipine, diltiazem, felodipine, isradipine, nifedipine,nicardipine , nimodipine, nisoldipine, verapamil | | Dihydropyridine calcium channel blockers | Caution is warranted and clinical monitoring of patients is recommended. |
| Corticosteroid: Dexamethasone | | Delavirdine | Use with caution. RESCRIPTOR may be less effective due to decreased delavirdine plasma concentrations in patients taking these agents concomitantly. |
| Erectile Dysfunction Agents: Sildenafil | | Sildenafil | Sildenafil should not exceed a maximum single dose of 25 mg in a 48 hours period. |
| HMG-CoA Reductase Inhibitors: Atorvastatin, Cerivastatin, Fluvastatin | | Atorvastatin | Cerivastatin | Fluvastatin | Use lowest possible dose of atorvastatin or cerivastatin, or fluvastatin with careful monitoring, or consider other HMG-CoA reductase inhibitors such as pravastatin in combination with RESCRIPTOR. |
| Immunosuppressants: Cyclosporine, Tacrolimus, Rapamycin | | Immuno- suppressants | Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with RESCRIPTOR. |
| Narcotic Analgesic: Methadone | | Methadone | Dosage of methadone may need to be decreased when co-administered with RESCRIPTOR. |
| Oral Contraceptives: Ethinyl estradiol | | Ethinyl estradiol | Concentrations of ethinyl estradiol may increase. However, the clinical significance is unknown. |
Indicates increase
-
Indicates decrease
*See CLINICAL PHARMACOLOGY for Magnitude of Interaction, Tables 1 and 2 Carcinogenesis, Mutagenesis and Impairment of Fertility: Delavirdine was negative in a battery of genetic toxicology tests which included an Ames assay, an in vitro rat hepatocyte unscheduled DNA synthesis assay, an in vitro chromosome aberration assay in human peripheral lymphocytes, an in vitro mutation assay in Chinese hamster ovary cells, and an in vivo micronucleus test in mice. Lifetime carcinogenicity studies were conducted in rats at doses of 10, 32 and 100 mg/kg/day and in mice at doses of 62.5, 250 and 500 mg/kg/day for males and 62.5, 125 and 250 mg/kg/day for females. In rats, delavirdine was noncarcinogenic at maximally tolerated doses that produced exposures (AUC) up to 12 (male rats) and 9 (female rats) times human exposure at the recommended clinical dose. In mice, delavirdine produced significant increases in the incidence of hepatocellular adenoma/adenocarcinoma in both males and females, hepatocellular adenoma in females, and mesenchymal urinary bladder tumors in males. The systemic drug exposures (AUC) in female mice were 0.5-3 fold and in male mice 0.2-4 fold of those in humans at the recommended clinical dose. Given the lack of genotoxic activity of delavirdine, the relevance of urinary bladder and hepatocellular neoplasm in delavirdine-treated mice to humans is not known. Delavirdine at doses of 20, 100, and 200 mg/kg/day did not cause impairment of fertility in rats when males were treated for 70 days and females were treated for 14 days prior to mating. Pregnancy: Pregnancy Category C: Delavirdine has been shown to be teratogenic in rats. Delavirdine caused ventricular septal defects in rats at doses of 50, 100, and 200 mg/kg/day when administered during the period of organogenesis. The lowest dose of delavirdine that caused malformations produced systemic exposures in pregnant rats equal to or lower than the expected human exposure to RESCRIPTOR (Cmin15 mM) at the recommended dose. Exposure in rats approximately 5-fold higher than the expected human exposure resulted in marked maternal toxicity, embryotoxicity, fetal developmental delay, and reduced pup survival. Additionally, reduced pup survival on postpartum day 0 occurred at an exposure (mean Cmin) approximately equal to the expected human exposure. Delavirdine was excreted in the milk of lactating rats at a concentration three to five times that of rat plasma. Delavirdine at doses of 200 and 400 mg/kg/day administered during the period of organogenesis caused maternal toxicity, embryotoxicity and abortions in rabbits. The lowest dose of delavirdine that resulted in these toxic effects produced systemic exposures in pregnant rabbits approximately 6-fold higher than the expected human exposure to RESCRIPTOR (Cmin15 mM) at the recommended dose. The no-observed-adverse-effect dose in the pregnant rabbit was 100 mg/kg/day. Various malformations were observed at this dose, but the incidence of such malformations was not statistically significantly different from those observed in the control group. Systemic exposures in pregnant rabbits at a dose of 100 mg/kg/day were lower than those expected in humans at the recommended clinical dose. Malformations were not apparent at 200 and 400 mg/kg/day; however, only a limited number of fetuses were available for examination as a result of maternal and embryo death. No adequate and well-controlled studies in pregnant women have been conducted. RESCRIPTOR should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Of 9 pregnancies reported in premarketing clinical studies and postmarketing experience, a total of 10 infants were born (including 1 set of twins). Eight of the infants were born healthy. One infant was born HIV-positive but was otherwise healthy and with no congenital abnormalities detected, and 1 infant was born prematurely (34 to 35 weeks) with a small muscular ventricular septal defect that spontaneously resolved. The patient received approximately six weeks of treatment with delavirdine and zidovudine early in the course of the pregnancy.
Antiretroviral Pregnancy Registry:
To monitor maternal-fetal outcomes of pregnant women exposed to RESCRIPTOR and other antiretroviral agents, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling (800) 258-4263.
Because of both the potential for HIV transmission and any possible adverse reactions in nursing infants,
Safety and effectiveness of delavirdine in combination with other antiretroviral agents
have not been established in HIV-1-infected individuals younger than 16 years of age.
Clinical studies of RESCRIPTOR did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, caution should be taken when dosing RESCRIPTOR in elderly patients due to the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy.
The safety of RESCRIPTOR Tablets alone and in combination with other therapies has been studied in approximately 6,000 patients receiving RESCRIPTOR. The majority of adverse events were of mild or moderate (ie, ACTG grade 1 or 2) intensity. The most frequently reported drug-related adverse event (ie, events considered by the investigator to be related to the blinded study medication, or events with an unknown or missing causal relationship to the blinded medication) among patients receiving RESCRIPTOR was skin rash (see Table 8 and PRECAUTIONS-Skin Rash).
Table 8: Percent of Patients with Treatment-Emergent Rash in Pivotal Trials (Studies 0021 Part II and 0013C)a
| Percent of Patients with: | Description of Rash Grade b | RESCRIPTOR 400 TID (n = 412) | Control Group Patients (n = 295) |
| Grade 1 Rash | Erythema, pruritis | 69 (16.7%) | 35 (11.9%) |
| Grade 2 Rash | Diffuse maculopapular rash, dry desquamation | 59 (14.3%) | 17 (5.8%) |
| Grade 3 Rash | Vesiculation, moist desquamation, ulceration | 18 (4.4%) | 0 (0.0%) |
| Grade 4 Rash | Erythema multiforme, Stevens- Johnson syndrome, toxic epideral necrolysis, necrosis requiring surgery, exfoliative dermatitis | 0 (0.0%) | 0 (0.0%) |
| Rash of any Grade | 146 (35.4%) | 52 (17.6%) | |
| Treatment discontinuation as a result of rash | 13 (3.2%) | 1 (0.3%) |
a
Includes events reported regardless of causality.
b
ACTG Toxicity Grading System, includes events reported as "rash", "maculopapular rash", and "urticaria".
Adverse events of moderate to severe intensity reported by at least 5% of evaluable patients in any treatment group in the pivotal trials, which includes patients receiving RESCRIPTOR in combination with zidovudine and/or lamivudine in Study 21 Part II for up to 98 weeks and in combination with zidovudine and either lamivudine, didanosine, or zalcitabine in Study 13C for up to 72 weeks are summarized in Table 9.
Table 9. Treatment-Emergent Events, Regardless of Causality, of Moderate to Severe or Life Threatening Intensity Reported by at Least 5% of Evaluablea Patients in any Treatment Group
| Study 21 Part II | Study 13C | ||||
| Adverse Events | ZDV + 3TC (N=123) | 400 mg tid RESCRIPTOR + ZDV (N=123) | 400 mg tid RESCRIPTOR + ZDV + 3TC (N=119) | ZDV + ddI, ddC or 3TC (N=172) | 400 mg tid RESCRIPTOR + ZDV + ddI, ddC or 3TC (N=170) |
| % of pts. (n) | % of pts. (n) | % of pts. (n) | % of pts. (n) | % of pts. (n) | |
| BODY AS A WHOLE | |||||
| Abdominal Pain Generalized | 2.4 (3) | 3.3 (4) | 5.0 (6) | 1.7 (3) | 2.4 (4) |
| Asthenia/Fatigue | 16.3 (20) | 15.4 (19) | 16.0 (19) | 8.1 (14) | 5.3 (9) |
| Fever | 2.4 (3) | 1.6 (2) | 3.4 (4) | 6.4 (11) | 7.1 (12) |
| Flu Syndrome | 4.9 (6) | 7.3 (9) | 5.0 (6) | 5.2 (9) | 2.4 (4) |
| Headache | 14.6 (18) | 12.2 (15) | 16.8 (20) | 12.8 (22) | 11.2 (19) |
| Localized Pain | 4.9 (6) | 5.7 (7) | 5.0 (6) | 2.9 (5) | 1.8 (3) |
| DIGESTIVE | |||||
| Diarrhea | 8.1 (10) | 2.4 (3) | 4.2 (5) | 8.1 (14) | 5.9 (10) |
| Nausea | 17.1 (21) | 20.3 (25) | 16.8 (20) | 9.3 (16) | 14.7 (25) |
| Vomiting | 8.9 (11) | 4.9 (6) | 2.5 (3) | 4.1 (7) | 6.5 (11) |
| NERVOUS | |||||
| Anxiety | 1.6 (2) | 2.4 (3) | 6.7 (8) | 4.1 (7) | 3.5 (6) |
| Depressive Symptoms | 6.5 (8) | 4.9 (6) | 12.6 (15) | 3.5 (6) | 5.9 (10) |
| Insomnia | 4.9 (6) | 4.9 (6) | 5.0 (6) | 2.9 (5) | 1.2 (2) |
| RESPIRATORY | |||||
| Bronchitis | 4.1 (5) | 6.5 (8) | 6.7 (8) | 3.5 (6) | 3.5 (6) |
| Cough | 9.8 (12) | 4.1 (5) | 5.0 (6) | 5.2 (9) | 3.5 (6) |
| Pharyngitis | 6.5 (8) | 1.6 (2) | 5.0 (6) | 4.1 (7) | 3.5 (6) |
| Sinusitis | 8.9 (11) | 7.3 (9) | 5.0 (6) | 2.3 (4) | 1.2 (2) |
| Upper Respiratory Infection | 11.4 (14) | 6.5 (8) | 7.6 (9) | 8.7 (15) | 4.7 (8) |
| SKIN | |||||
| Rashes | 3.3 (4) | 19.5 (24) | 13.4 (16) | 7.6 (13) | 18.8 (32) |
a
Evaluble patients in Study 21 Part II were those who received at least 1 dose of study medication and returned for at least 1 clinic study visit. Evaluble patients in Study 13C were those who received at least 1 dose of study medication.
Other adverse events that occurred in patients receiving RESCRIPTOR (in combination treatment) in all phase II and III studies, and considered possibly related to treatment, and of at least ACTG grade 2 in intensity are listed below by body system.
Body as a Whole:
Abdominal cramps, abdominal distention, abdominal pain (localized), abscess, allergic reaction, chills, edema (generalized or localized), epidermal cyst, fever, infection, infection viral, lip edema, malaise, mMycobacterium Ttuberculosis Iinfection, neck rigidity, and sebaceous cyst.
Cardiovascular System:
Abnormal cardiac rate and rhythm, cardiac insufficiency, cardiomyopathy, hypertension, migraine, pallor, peripheral vascular disorder, and postural hypotension.
Digestive System: Anorexia, bloody stool, colitis, constipation, decreased appetite, diarrhea (Clostridium difficile), diverticulitis, dry mouth, dyspepsia, dysphagia, enteritis at all levels, eructation, fecal incontinence, flatulence, gagging, gastroenteritis, gastroesophageal reflux, gastrointestinal bleeding, gastrointestinal disorder, gingivitis, gum hemorrhage, hepatomegaly, increased appetite, increased saliva, increased thirst, jaundice, mouth or tongue inflammation or ulcers, nonspecific hepatitis, oral/enteric moniliasis, pancreatitis, rectal disorder, sialadenitis, tooth abscess, and toothache. Hemic and Lymphatic System: Adenopathy, bruising, eosinophilia, granulocytosis, leukopenia, pancytopenia, purpura, spleen disorder, thrombocytopenia, and prolonged prothrombin time. Metabolic and Nutritional Disorders: Alcohol intolerance, amylase increased, bilirubinemia, hyperglycemia, hyperkalemia, hypertriglyceridemia, hyperuricemia, hypocalcemia, hyponatremia, hypophosphatemia, increased AST (SGOT), increased gamma glutamyl transpeptidase, increased lipase, increased serum alkaline phosphatase, increased serum creatinine, and weight increase or decrease. Musculoskeletal System: Arthralgia or arthritis of single and multiple joints, bone disorder, bone pain, myalgia, tendon disorder, tenosynovitis, tetany, and vertigo.
Nervous System:
Abnormal coordination, agitation, amnesia, change in dreams, cognitive impairment, confusion, decreased libido, disorientation, dizziness, emotional lability, euphoria, hallucination, hyperesthesia, hyperreflexia, hypertonia, hypesthesia, impaired concentration, manic symptoms, muscle cramp, nervousness, neuropathy, nystagmus, paralysis, paranoid symptoms, restlessness, sleep cycle disorder, somnolence, tingling, tremor, vertigo, and weakness.
Respiratory System:
Chest congestion, dyspnea, epistaxis, hiccups, laryngismus, pneumonia, and rhinitis.
Skin and Appendages:
Angioedema, dermal leukocytoclastic vasculitis, dermatitis, desquamation, diaphoresis, discolored skin, dry skin, erythema, erythema multiforme, folliculitis, fungal dermatitis, hair loss, herpes zoster or simplex, nail disorder, petechiae, pruritus non-application site, seborrhea, skin hypertrophy, skin disorder, skin nodule, Stevens-Johnson syndrome, urticaria, vesiculobullous rash, and wart.
Special Senses:
Blepharitis, blurred vision, conjunctivitis, diplopia, dry eyes, ear pain, parosmia, otitis media, photophobia, taste perversion, tinnitus.
Urogenital System:
Amenorrhea, breast enlargement, calculi of the kidney, chromaturia, epididymitis, hematuria, hemospermia, infection urinary tract, impaired urination, impotence, kidney pain, metrorrhagia, nocturia, polyuria, proteinuria, testicular pain, and vaginal moniliasis.
Post-Marketing Experience:
Adverse event terms reported from postmarking surveillance that were not reported in the phase II and III trials are presented below.
Digestive System:
Hepatic failure.
Hemic and Lymphatic System:
Hemolytic anemia.
Musculoskeletal System:
Rhabdomyolysis.
Urogenital System:
Acute kidney failure.
Laboratory Abnormalities:
Marked laboratory abnormalities observed in at least 2% of patients during Studies 21 Part II and 13C are summarized in Table 10. Marked laboratory abnormalities are defined as any Grade 3 or 4 abnormality found in patients at any time during study.
Table 10. Marked Laboratory Abnormalities Reported by 3 2% of Patients
| Study 21 Part II | Study 13C | |||||
| Adverse Events | Toxicity Limit | ZDV + 3TC N=122 | 400 mg tid RESCRIPT OR + ZDV | 400 mg tid RESCRIPT OR + ZDV + 3TC | ZDV + ddI, ddC or 3TC | 400 mg tid RESCRIP TOR + ZDV + ddI, ddC or 3TC |
| % pts. | % pts. | % pts. | % pts. | % pts. | ||
| Hematology | ||||||
| Hemoglobin | < 7 mg/dL | 4.1 | 2.5 | 0.9 | 1.7 | 2.9 |
| Neutrophils | <750/mm 3 | 5.7 | 4.9 | 3.4 | 10.4 | 7.6 |
| Prothrombin time (PT) | >1.5 x ULN | 0 | 0 | 1.7 | 2.9 | 2.4 |
| Activated partial thromboplast in (APTT) | >2.33 x ULN | 0 | 0.8 | 0 | 5.8 | 2.4 |
| Chemistry | ||||||
| Alananine aminotransfer -ase (ALT / SGPT) | >5 x ULN | 2.5 | 4.1 | 5.1 | 3.5 | 4.1 |
| Amylase | >2 x ULN | 0.8 | 2.5 | 2.6 | 3.5 | 2.9 |
| Aspartate aminotransfer -ase (AST/SGOT) | >5 x ULN | 1.6 | 2.5 | 3.4 | 3.5 | 2.3 |
| Bilirubin | >2.5 x ULN | 0.8 | 2.5 | 1.7 | 1.2 | 0 |
| Gamma glutamyl transferase (GGT) | >5 x ULN | N/A | N/A | N/A | 4.1 | 1.8 |
| Glucose (hypo- /hyperglycem ia) | <40 mg/dL >250 mg/dL | 4.1 | 0.8 | 1.7 | 1.2 | 0.0 |
NA=not applicable because no predose values were obtained for patients.
Human experience of acute overdose with RESCRIPTOR is limited.
Treatment of overdosage with RESCRIPTOR should consist of general supportive measures, including monitoring of vital signs and observation of the patient's clinical status. There is no specific antidote for overdosage with RESCRIPTOR. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage. Since delavirdine is extensively metabolized by the liver and is highly protein bound, dialysis is unlikely to result in significant removal of the drug.
The recommended dosage for RESCRIPTOR Tablets is 400 mg (four 100-mg or two 200-mg tablets) three times daily. RESCRIPTOR should be used in combination with other antiretroviral therapy. The complete prescribing information for other antiretroviral agents should be consulted for information on dosage and administration. The 100-mg RESCRIPTOR Tablets may be dispersed in water prior to consumption. To prepare a dispersion, add four 100-mg RESCRIPTOR Tablets to at least 3 ounces of water, allow to stand for a few minutes, and then stir until a uniform dispersion occurs (see CLINICAL PHARMACOLOGY- Pharmacokinetics-Absorption and Bioavailability). The dispersion should be consumed promptly. The glass should be rinsed with water and the rinse swallowed to insure the entire dose is consumed. The 200-mg tablets should be taken as intact tablets, because they are not readily dispersed in water. Note: The 200-mg tablets are approximately one third smaller in size than the 100-mg tablets. RESCRIPTOR Tablets may be administered with or without food (see CLINICAL PHARMACOLOGY- Pharmacokinetics-Absorption and Bioavailability). Patients with achlorhydria should take RESCRIPTOR with an acidic beverage (eg, orange or cranberry juice). However, the effect of an acidic beverage on the absorption of delavirdine in patients with achlorhydria has not been investigated. Patients taking both RESCRIPTOR and antacids should be advised to take them at least one hour apart.
RESCRIPTOR Tablets are available as follows: 100 mg: white, capsule-shaped tablets marked with "U 3761". Bottles of 360 tablets NDC 63010-020-36 200 mg: white, capsule-shaped tablets marked with "RESCRIPTOR 200 mg". Bottles of 180 tablets NDC 63010-021-18 Store at controlled room temperature 20deg to 25degC (68deg to 77degF) [see USP]. Keep container tightly closed. Protect from high humidity. Rx only
Toxicities among various organs and organ systems in rats, mice, rabbits, dogs, and monkeys were observed following the administration of delavirdine. Necrotizing vasculitis was the most significant toxicity that occurred in dogs when mean nadir serum concentrations of delavirdine were at least 7-fold higher than the expected human exposure to RESCRIPTOR (Cmin15 mM) at the recommended dose. Vasculitis in dogs was not reversible during a 2.5-month recovery period; however, partial resolution of the vascular lesion characterized by reduced inflammation, diminished necrosis, and intimal thickening occurred during this period. Other major target organs included the gastrointestinal tract, endocrine organs, liver, kidneys, bone marrow, lymphoid tissue, lung, and reproductive organs. Agouron Pharmaceuticals, Inc. La Jolla, CA 92037, USA RESCRIPTOR is a registered trademark of Pharmacia & Upjohn Company. L416-000 Revised 5/15/01 816 885 005A Agouron Pharmaceuticals, Inc.
Patient Prescribing Information
RESCRIPTOR
ALERT: Find out about medicines that should NOT be taken with RESCRIPTOR. Please also read the section "MEDICINES YOU SHOULD NOT TAKE WITH RESCRIPTOR."